Overview

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

Status:
Withdrawn

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

The proposed research is intended to determine if supplementation of relatively high dose vitamin D in chronic urticaria patients receiving omalizumab will result in continued symptomatic control of hives after the discontinuation of omalizumab.

Phase:

Phase 4

Details

Lead Sponsor:

Selina Gierer, D.O.

Treatments:

Ergocalciferols
Omalizumab
Vitamin D
Vitamins